Cargando…
The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment-naïve patients
The ZIPANGU study assessed the efficacy and safety of ranibizumab as a one loading dose + pro re nata (one + PRN) regimen with/without focal/grid laser among treatment-naïve patients suffering from macular edema (ME) following branch retinal vein occlusion (BRVO). ZIPANGU was a phase IV, prospective...
Autores principales: | Murata, Toshinori, Kondo, Mineo, Inoue, Makoto, Nakao, Shintaro, Osaka, Rie, Shiragami, Chieko, Sogawa, Kenji, Mochizuki, Akikazu, Shiraga, Rumiko, Ohashi, Yohei, Kaneko, Takeumi, Chandrasekhar, Chikatapu, Tsujikawa, Akitaka, Kamei, Motohiro |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7804316/ https://www.ncbi.nlm.nih.gov/pubmed/33436683 http://dx.doi.org/10.1038/s41598-020-79051-1 |
Ejemplares similares
-
Author Correction: The randomized ZIPANGU trial of ranibizumab and adjunct laser for macular edema following branch retinal vein occlusion in treatment‑naïve patients
por: Murata, Toshinori, et al.
Publicado: (2021) -
Estimating ranibizumab injection numbers and visual acuity at 12 months based on 2-month data on branch retinal vein occlusion treatment
por: Murata, Toshinori, et al.
Publicado: (2022) -
Effect of topical isopropyl unoprostone on macular atrophy progression in eyes with exudative age-related macular degeneration
por: Shiragami, Chieko, et al.
Publicado: (2017) -
CLINICAL FEATURES OF TREATED AND UNTREATED TYPE 1 IDIOPATHIC MACULAR TELANGIECTASIA WITHOUT THE OCCURRENCE OF SECONDARY CHOROIDAL NEOVASCULARIZATION FOLLOWED FOR 2 YEARS IN JAPANESE PATIENTS
por: Osaka, Rie, et al.
Publicado: (2018) -
MACULAR ATROPHY FINDINGS BY OPTICAL COHERENCE TOMOGRAPHY ANGIOGRAPHY COMPARED WITH FUNDUS AUTOFLUORESCENCE IN TREATED EXUDATIVE AGE-RELATED MACULAR DEGENERATION
por: Takasago, Yukari, et al.
Publicado: (2019)